Open AccessHepatitis E associated fulminant hepatic failure and its outcome in pregnancy.
Author(s) -
Zahida Parveen Brohi,
Uzma Parveen,
Aneela Sadaf
Publication year - 2020
Publication title -
the professional medical journal/the professional medical journal
Language(s) - English
Resource type - Journals
eISSN - 2071-7733
pISSN - 1024-8919
DOI - 10.29309/tpmj/2020.27.10.4218
Subject(s) - medicine , fulminant hepatic failure , pregnancy , obstetrics , miscarriage , fulminant , obstetrics and gynaecology , fulminant hepatitis , pediatrics , retrospective cohort study , hepatitis , viral hepatitis , gynecology , liver transplantation , transplantation , genetics , biology
Objectives: To determine the clinical features and outcome of hepatitis E associated fulminant hepatic failure in pregnancy. Study Design: Observational Retrospective study. Setting: Department of Obstetrics & Gynecology at Isra University Hospital Hyderabad. Period: Three years from 1st January 2015 to 31st December 2017. Material & Methods: Total 3596 obstetric patients were admitted whom 168 pregnant women who were positive for hepatitis E viral marker have been included in the study. Results: Their age was between 18 to 47 years with mean age 26.04±6.40 years; majority of patients had not received antenatal care 123 (73.2%). Out of 168, 27 (16%) presented in the first trimester, 45 (26.7%) presented in the second trimester, while 96 (57.1%) patients developed fulminant hepatic failure in their 3rd trimester of pregnancy. Out of 168, 111(66%) patients delivered and 57 (33.9%) were undelivered. Fetal and perinatal outcome of delivered patients showed miscarriage 45 (40.5%), stillborn 25(14.8%), preterm delivery 17(15.3%), neonatal death 7 (6.3%) and 17 (15.3%) new born remained alive. Overall maternal mortality was 51 (30.3%). Conclusion: Hepatitis – E related fulminant hepatic failure in pregnancy is a troublesome clinical issue and connected with exceptionally high maternal and fetal mortality. Appropriate diagnosis, early timely intervention can considerably diminish the morbidity and mortality associated with (HEV) Fulminant hepatic failure.